Medy-Tox Delays Cancellation of Redeemable Convertible Preferred Shares to September 2026
Medy-Tox completed the redemption of all 440,635 redeemable convertible preferred shares on February 23, 2026, and finalized the registration change, but due to delays in the account transfer process for electronic cancellation, the expected cancellation date has been postponed from June 30, 2026 to September 30, 2026.
The cancellation is funded from distributable profits, so no capital reduction occurs; upon completion, the 440,635 preferred shares will be extinguished, slightly increasing the per-share value of common shares.
The date change is an administrative adjustment due to procedural delays, with no modification to financial terms or the scale of cancellation, thus limiting the impact on shareholder value.
[AI Summary]The postponement of Medy-Tox's preferred share cancellation date is an unavoidable adjustment due to delays in the electronic cancellation process, involving no financial changes or new capital raising. The cancellation of 440,635 shares representing about 6% of total shares is merely delayed, not canceled, so the impact on stock price is neutral.
KOSDAQ Filing Information
[Correction of Description] Decision to Retire Shares (Redeemable Convertible Preferred Stock)